Brokerages Set Sanofi (NASDAQ:SNY) PT at $60.00

Shares of Sanofi (NASDAQ:SNY) have been assigned a consensus rating of “Buy” from the four analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $60.00.

A number of equities research analysts have recently commented on SNY shares. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $53.35 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The firm has a 50-day simple moving average of $49.34 and a 200 day simple moving average of $52.32. The company has a market cap of $135.39 billion, a PE ratio of 21.43, a P/E/G ratio of 1.26 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. On average, sell-side analysts anticipate that Sanofi will post 4.34 EPS for the current year.

Hedge Funds Weigh In On Sanofi

A number of hedge funds have recently bought and sold shares of SNY. Oxbow Advisors LLC increased its stake in shares of Sanofi by 4.8% during the fourth quarter. Oxbow Advisors LLC now owns 104,749 shares of the company’s stock valued at $5,052,000 after acquiring an additional 4,790 shares during the period. Bank of Stockton lifted its stake in shares of Sanofi by 6.0% in the 4th quarter. Bank of Stockton now owns 6,251 shares of the company’s stock valued at $301,000 after purchasing an additional 352 shares during the last quarter. Transcend Capital Advisors LLC lifted its stake in shares of Sanofi by 5.3% in the 4th quarter. Transcend Capital Advisors LLC now owns 5,623 shares of the company’s stock valued at $271,000 after purchasing an additional 281 shares during the last quarter. Waterfront Wealth Inc. lifted its position in Sanofi by 46.0% during the 4th quarter. Waterfront Wealth Inc. now owns 49,958 shares of the company’s stock worth $2,409,000 after acquiring an additional 15,748 shares during the last quarter. Finally, Concurrent Investment Advisors LLC lifted its position in Sanofi by 2.6% during the 4th quarter. Concurrent Investment Advisors LLC now owns 37,946 shares of the company’s stock worth $1,830,000 after acquiring an additional 973 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.